Susan Vogt serves as Independent Director of the Company. She served as President and Chief Executive Officer of Aushon Biosystems, Inc., a developer of a multiplex immunoassay platform, from 2013 until the company was acquired by Quanterix Corporation in January 2018. From 2006 to 2011, Ms. Vogt was President and Chief Executive Officer of Seracare Life Sciences, Inc., a Nasdaq-listed life sciences developer of products facilitating human diagnostics and therapeutics. From 1981 to 2005, she served in various officer positions at Millipore Corporation (now part of MillaporeSigma, the life science business of Merck KGaA), an NYSE-listed developer of biotechnology and pharmaceutical drug therapies, including as President of the Biopharmaceutical Division, Vice President and General Manager of the Laboratory Water Division, Vice President and General Manager of the Analytical Products Division, Vice President and General Manager of the Analytical Division, and Finance Manager, Division Controller. Ms. Vogt received her M.B.A. from Boston University with a concentration in Finance and her B.A. from Brown University in Art History.
As the Independent Director of Anika Therapeutics, the total compensation of Susan Vogt at Anika Therapeutics is $184,980. There are 12 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
Susan Vogt is 66, she's been the Independent Director of Anika Therapeutics since 2018. There are 2 older and 14 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia e Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
Anika Therapeutics executives and other stock owners filed with the SEC include: